Critical Outcome Technologies Inc.

Advancing the Treatment of Cancer Through Targeted Therapeutics

November 2015

Notice to reader

Critical Outcome Technologies Inc.

This presentation may contain information, and management may make statements, other than historical facts that constitute "forward-looking statements" as such term is used in applicable United States and Canadian laws. These statements relate to analyses, plans and other information that are based on forecasts of future results, estimates of amounts not yet determinable, events not yet started or completed and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "targets", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and should be viewed as "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Critical Outcome Technologies Inc. (COTI) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others: COTI's ability to raise sufficient financing for continuing operations and development activities; COTI's ability to realize favourable clinical test results from COTI's lead oncology compound, COTI-2; COTI's ability to meet future regulatory requirements to commercialize compounds – in particular, COTI-2; COTI's ability to establish customer relationships leading to licensing agreements for COTI's compounds; COTI's ability to generate customer demand for outputs from the CHEMSAS® technology; and COTI's ability to obtain patent protection for its compounds. Although COTI has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, viewers of this presentation should not place undue reliance on forward-looking statements made in the presentation and in any document referred to in the presentation.

Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and COTI undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions many of which are outlined in detail in the Company's Annual Information Form found on SEDAR.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities of COTI. Distribution of this presentation or the disclosure of its contents to anyone without the express written permission of COTI is prohibited.

Critical Outcome Technologies Inc.

A clinical stage biopharmaceutical company with a promising new drug for ovarian and other cancers with p53 mutations

- TSX-V: COT
- OTCQB: COTQF

Investment highlights

Critical Outcome Technologies Inc.

1. COTI-2: p53 activating drug entering Phase 1
   - > 95% of ovarian cancer patients have a p53 gene mutation
   - > $1B market potential in U.S. alone
2. Strong pipeline of follow-on opportunities in oncology and other therapeutic areas
3. Approaching a critical inflection point

COTI-2: A breakthrough for many cancers

Critical Outcome Technologies Inc.

- p53 is the single most important cancer causing gene mutation known
  - > 50% of all human cancers
- Novel mechanism of action reactivates p53 function
- Effective against many common cancers in preclinical animal models

"a promising advance for many cancers with p53 mutations." – Dr. G.B. Mills, MDACC



COTI-2: Strong market opportunity

Critical Outcome Technologies Inc.

- ~ 12 million new cases of cancer annually worldwide
  - ~ 30% of all cancers would have susceptible p53 mutations
- Exploring clinical studies for multiple indications:
  - Head and neck (orphan) – next Phase 1 study in 2016
  - AML (orphan)
  - Li-Fraumeni syndrome (orphan)
- Preclinical models with COTI-2 demonstrate effectiveness when combined with many first-line therapies:
  - Chemotherapy and Immunotherapy

Advancing the treatment of p53-dependent cancers

COTI-2: Best-in-class potential

Critical Outcome Technologies Inc.

- Novel p53-dependent mechanism of action
- Orally bio-available and effective at low dose
- Low toxicity in preclinical development
- Opportunity for single agent and combination therapy
- Strong IP protection in place
  - 6 U.S. patents issued
  - 1 Japanese, 1 Canadian and 1 EU patent issued
  - Additional patents pending

COTI-2: Significant tumor reduction

Critical Outcome Technologies Inc.



Tumor volumes significantly reduced by COTI-2 in all treatment groups relative to vehicle control

Competitor comparison to COTI-2

Critical Outcome Technologies Inc.

DRUG	COTI-2	Kevetrin	APR-246 / PRIMA-1^{MET}
COMPANY	Critical Outcome Technologies Inc.	Cellceutix Corp	Aprea
MECHANISM OF ACTION	Targets mutant p53 (restoration of wild-type p53 conformation and activity)	Targets wild-type and mutant p53 (MDM2-related mechanism)	Targets mutant p53 (restoration of wild-type p53 conformation and activity)
IN VITRO EFFICACY	Most potent (nanomolar range of activity)	Least potent (activity >100 µM)	Much less potent than COTI-2 (activity in high micromolar range)
CLINICAL PHASE OF DEVELOPMENT	Phase 1	Phase 1	Phase 1/2
INDICATIONS	Gynecological malignancies (first patient in fall 2015)	Solid tumors (ongoing)	Hematological malignancies and prostate cancer (phase 1/2 completed)

MD Anderson collaboration

Critical Outcome Technologies Inc.



- Key Opinion Leader, Dr. Gordon Mills, independently confirmed COTI-2's novel p53-dependent mechanism of action
- Confirmed COTI-2's selective & potent anti-cancer activity
- Identified effective dosage 60% lower than in prior animal experiments
- MDACC has committed financial support to a Phase 1

Advancing success to clinical studies

Critical Outcome Technologies Inc.

- *In vitro* and *in vivo* studies done with human cancer cell lines
- Toxicity studies show limited toxicity and dosing level relatively low for seeing results
- Dr. Mills has stated that based on his long experience results seen to date should translate to people
- Queen's University study – clinical success where there are 5 or more preclinical cancer indications

COTI-2: Important milestones

Critical Outcome Technologies Inc.

COMPLETED

- ✓ Granted orphan drug status for ovarian cancer by FDA in June 2014
- ✓ Signed LOI with MD Anderson for Phase 1 clinical trial in August 2014
- ✓ Appointed experienced Scientific Advisory Board (SAB)
- ✓ IND grant to proceed from FDA on May 22, 2015
- ✓ Obtained financing of ~ $1.97 million CAD during summer 2015

UPCOMING

- ✓ Phase 1 clinical trial initiated December 2015
- ○ Increase value of COTI-2 by identifying new clinical indications and combination therapies
- ○ Select next preclinical candidate for development
- ○ Develop additional collaborations and partnerships with COTI-2 and CHEMSAS®
- ○ COTI-2 publications 2016

COTI-2: First of many opportunities

Critical Outcome Technologies Inc.



* Other programs for MRSA, Multiple Sclerosis, Alzheimer's, and HIV Integrase

Building a robust pipeline with CHEMSAS®

Critical Outcome Technologies Inc.

- Proprietary, machine learning (AI) based drug discovery platform technology
- Big data analysis solutions

Advantages of CHEMSAS®

Critical Outcome Technologies Inc.

Database driven computational replication of traditional 'wet lab' drug discovery process

Costly failed attempts occur **quickly & cheaply** in computer simulations, not the 'wet lab'

Increased probability of clinical & commercial success

Next clinical candidate options

Critical Outcome Technologies Inc.

1. COTI-219, a unique oncology drug candidate for CRC and melanoma
2. COTI-AML-01, a multi-kinase inhibitor for Acute Myelogenous Leukemia (AML)
3. COTI-HIV-II, second generation dual HIV Integrase inhibitor
4. COTI-MRSA1, highly novel antibiotic

All pipeline candidates discovered by CHEMSAS®

Established R&D collaborations

Critical Outcome Technologies Inc.

- Two R&D collaborations in progress:
  - Western University
  - Delmar Chemicals
- Third collaboration with a medium sized pharma in early discussions

Actively pursuing additional R&D collaboration opportunities with CHEMSAS®

Committed leadership

Critical Outcome Technologies Inc.

Management Team

Wayne Danter, MD, FRCPC
- Co-founder, President, CEO & CSO
- Former Associate Professor of Medicine at Western University

Gene Kelly
- Chief Financial Officer
- Former VP Finance, Cuddy Farms
- Former VP Commodities & Industry Relations, Cuddy Foods
- Former VP Strategic Implementations, Cuddy Farms

Kowthar Salim, PhD, MBA
- Program Director and Senior Scientist

Alison Silva, MS
- Co-founder, EVP & COO, Synlogic

Directors

John Drake, LLB, Chairman
- Chairman, Whippoorwill Holdings Limited

Wayne Danter, MD, FRCPC

Douglas Alexander, CPA, CA
- Chairman, Hydrogenics Corporation

Bruno Maruzzo, MASc, MBA
- President, TechnoVenture Inc.

Dave Sanderson, LLB
- President & CEO, KFL Investment Management Inc.

Alison Silva, MS
- Co-founder, EVP & COO, Synlogic

John Yoo, MD FRCPC
- Professor, Chairman and City-wide Chief of Otolaryngology – Head and Neck Surgery at Western University

COTI-2 Scientific Advisory Board

Critical Outcome Technologies Inc.

Dr. Gordon Mills from the University of Texas MD Anderson Cancer Center, Houston, TX, Chairman

Dr. Douglas Levine from the Memorial Sloan-Kettering Cancer Center in New York City, NY

Dr. David Parkinson from New Enterprise Associates in Menlo Park, CA

Dr. Marshall Strome from the Center for Head and Neck Oncology at Roosevelt St. Luke's Hospital in New York City, NY

Dr. Wayne R. Danter, Chief Scientific Officer, Critical Outcome Technologies Inc, London, Canada

Key Company Facts

Critical Outcome Technologies Inc.

Trading	
TSX Venture [2]	COT
Recent Closing Price [3]	$0.295
52 Week Range [3]	$0.195 - 0.375
Market Capitalization [3]	$37,391,185
Capital	
Cash [4]	$2,474,092
Basic Shares Outstanding [3]	126,749,781
Options Outstanding [3]	7,145,470
Warrants Outstanding [3]	45,539,152
Fully Diluted Shares Outstanding [3]	179,434,403
Board & management control [3] [5]	16.2%

(1) All $ amounts in CAD
(2) COTI also trades on the OTCQB:COTQF but amounts presented are for the TSXV only
(3) As at Oct 31, 2015
(4) As at Oct 8, 2015 consisting of cash, cash equivalents and short-term investment
(5) On a fully diluted basis

Contact:
Dr. Wayne Danter
President & CEO
Office: (519) 858-5157
Mobile: (519) 851-0035
wdanter@criticaloutcome.com

www.criticaloutcome.com
www.criticaloutcomeblog.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome